JP2013521273A5 - - Google Patents

Download PDF

Info

Publication number
JP2013521273A5
JP2013521273A5 JP2012555537A JP2012555537A JP2013521273A5 JP 2013521273 A5 JP2013521273 A5 JP 2013521273A5 JP 2012555537 A JP2012555537 A JP 2012555537A JP 2012555537 A JP2012555537 A JP 2012555537A JP 2013521273 A5 JP2013521273 A5 JP 2013521273A5
Authority
JP
Japan
Prior art keywords
done
maximum
diffraction spectrum
milling method
ray spectral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012555537A
Other languages
English (en)
Japanese (ja)
Other versions
JP5932669B2 (ja
JP2013521273A (ja
Filing date
Publication date
Priority claimed from ITMI2010A000370A external-priority patent/IT1398550B1/it
Application filed filed Critical
Publication of JP2013521273A publication Critical patent/JP2013521273A/ja
Publication of JP2013521273A5 publication Critical patent/JP2013521273A5/ja
Application granted granted Critical
Publication of JP5932669B2 publication Critical patent/JP5932669B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012555537A 2010-03-05 2011-03-04 リファキシミン粉体、その調製方法、及び長期持続効果を得るために有用な前記リファキシミン含有徐放性組成物 Expired - Fee Related JP5932669B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2010A000370 2010-03-05
ITMI2010A000370A IT1398550B1 (it) 2010-03-05 2010-03-05 Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
PCT/IB2011/050933 WO2011107970A2 (en) 2010-03-05 2011-03-04 Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect.

Publications (3)

Publication Number Publication Date
JP2013521273A JP2013521273A (ja) 2013-06-10
JP2013521273A5 true JP2013521273A5 (enExample) 2014-01-30
JP5932669B2 JP5932669B2 (ja) 2016-06-08

Family

ID=42697389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012555537A Expired - Fee Related JP5932669B2 (ja) 2010-03-05 2011-03-04 リファキシミン粉体、その調製方法、及び長期持続効果を得るために有用な前記リファキシミン含有徐放性組成物

Country Status (27)

Country Link
US (2) US8748447B2 (enExample)
EP (1) EP2542225B1 (enExample)
JP (1) JP5932669B2 (enExample)
KR (1) KR101663491B1 (enExample)
CN (1) CN102781432B (enExample)
AU (1) AU2011222432B2 (enExample)
BR (1) BR112012021681A8 (enExample)
CA (1) CA2787123C (enExample)
CL (1) CL2012002124A1 (enExample)
CO (1) CO6551760A2 (enExample)
DK (1) DK2542225T3 (enExample)
EA (1) EA022324B1 (enExample)
ES (1) ES2496771T3 (enExample)
HR (1) HRP20140876T1 (enExample)
IL (1) IL220792A (enExample)
IT (1) IT1398550B1 (enExample)
MX (1) MX2012010233A (enExample)
NZ (1) NZ602230A (enExample)
PL (1) PL2542225T3 (enExample)
PT (1) PT2542225E (enExample)
RS (1) RS53609B1 (enExample)
SG (1) SG182523A1 (enExample)
SI (1) SI2542225T1 (enExample)
TN (1) TN2012000362A1 (enExample)
UA (1) UA107208C2 (enExample)
WO (1) WO2011107970A2 (enExample)
ZA (1) ZA201205537B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
WO2016019372A1 (en) * 2014-08-01 2016-02-04 Bioxcel Corporation Methods for reformulating and repositioning pharmaceutical data and devices thereof
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2016181276A1 (en) * 2015-05-08 2016-11-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
WO2017162725A1 (en) 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
WO2017162726A1 (en) 2016-03-24 2017-09-28 Sandoz Ag Storage stable composition comprising rifaximin alpha
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
WO2020208140A1 (en) * 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
WO2023067485A1 (en) * 2021-10-19 2023-04-27 Zydus Lifesciences Limited Pharmaceutical combinations
WO2025170483A1 (ru) * 2024-02-07 2025-08-14 Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП" Фармацевтическая композиция, обладающая антибиотической активностью

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
DE3113139A1 (de) 1981-04-01 1982-10-21 Smit Transformatoren B.V., 6500 Nijmegen "trockentransformator oder drosselspule mit luftkuehlung"
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
WO1992000302A1 (en) 1990-06-29 1992-01-09 Gruppo Lepetit S.P.A. Pure crystalline form of rifapentine
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ,インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100338028C (zh) 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
JP2010504314A (ja) * 2006-09-22 2010-02-12 シプラ・リミテッド リファキシミン
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2389358T5 (es) 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
US8383151B2 (en) 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
MX2010009389A (es) 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
SG10201501054TA (en) 2009-10-27 2015-04-29 Lupin Ltd Solid dispersion of rifaximin
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
CN102724960A (zh) 2009-11-23 2012-10-10 希普拉有限公司 局部泡沫组合物
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011110930A2 (en) 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
JP2013527246A (ja) 2010-06-03 2013-06-27 サリックス ファーマシューティカルズ リミテッド リファキシミンの型およびその使用
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
CA2804635C (en) 2010-07-12 2019-09-10 Salix Pharmaceuticals, Ltd. Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
BR112013005772A2 (pt) 2010-09-13 2019-09-24 Cipla Ltd composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
MX350448B (es) 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k

Similar Documents

Publication Publication Date Title
JP2013521273A5 (enExample)
ZA201107806B (en) Organisms for the production of 1,3-butanediol
JP2014102408A5 (enExample)
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
JP2012190484A5 (enExample)
JP2012081521A5 (enExample)
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
JP2011510317A5 (enExample)
GB2485667B (en) Controlling hydrogen-deuterium exchange on a spectrum by spectrum basis
JP2012035359A5 (enExample)
IL216935A0 (en) Process for the preparation of nacre mechano-structured by mechanosynthesis, mechano-structured nacre thus obtained and uses thereof
MX2013013463A (es) Nuevo procedimiento para la síntesis de rifaximina y una nueva forma pseudocristalina de rifaximina obtenida con el mismo.
PL2901857T3 (pl) Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu
JP2011234359A5 (enExample)
JP2013528272A5 (enExample)
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
WO2015022265A3 (en) Cyclobutyl carboxamides as nematicides
EP2687520A4 (en) PROCESS FOR PREPARING A 1,2-BENZISOTHIAZOL-3-ON COMPOUND
IL232194A0 (en) An improved iontophoretic cross-linking mixture for use in the treatment of keratoconus
EP2883870B8 (en) Method for producing 1,4-benzoxazine compound
WO2016016774A8 (en) Crystalline forms of canagliflozin
JP2014507254A5 (enExample)
WO2013121439A3 (en) Garenoxacin mesylate, process for preparation thereof, and crystalline form thereof.
PL2771328T3 (pl) Sposób otrzymywania 1,2-benzizotiazolin-3-onu